Pilot study for the development of a new campylobacter selective medium at 37°C using aztreonam

G D Thomas

Aims: To overcome contamination and temperature inhibition by isolating campylobacter at 37°C.

Methods: The β-lactam antibiotic aztreonam was included in a selective medium because of its inhibitory activity against Gram negative organisms but not against Campylobacter jejuni. Vancomycin and amphotericin were added to inhibit Gram positive bacteria and yeasts.

Results: The aztreonam amphotericin vancomycin (AAV) experimental campylobacter selective medium showed growth microaerobically at 37°C of C. jejuni, C. coli, C. hyointestinalis, C. fetus subsp. fetus, and C. jejuni subsp. doylei after 24 to 48 hours of incubation. Six campylobacter NCTC strains demonstrated a minimum inhibitory concentration (MIC) > 256 mg/litre for vancomycin and aztreonam, whereas C. upsaliensis and two “campylobacter-like” strains now reclassified under genus helicobacter—H. cinaedi and H. fennelliae—had a MIC of 4 mg/litre for vancomycin and aztreonam. In the pilot study (150 samples), AAV medium (37°C) had a higher sensitivity for isolating campylobacters; 14 were isolated on AAV compared with 10 on modified CDA (43°C) over three days, and nine were isolated on AAV medium compared with five on modified CDA (43°C) after 24 hours of incubation. Contamination rates remained low.

Conclusion: The medium was devised in a pilot study performed between 1990 and 1993; however, this is the first report of AAV medium used as a selective medium capable of growing six campylobacters of pathogenic importance at 37°C. Further studies are indicated.

Campylobacter isolation requires a simple medium that uses antibiotics as selective agents. These antibiotics vary from the “cocktail” of vancomycin, polymyxin B, and trimethoprim found in Skirrow’s medium, to a single antibiotic (cefazolin) in CDA, and cefoperazone in modified CDA; in addition, less inhibitory agents have also been advocated, such as teicoplanin in CAT medium. However, Campylobacter jejuni and C. coli remain the two main pathogens responsible for campylobacter enteritis, and early diagnosis by culture and isolation can enhance clinical investigation. The recovery of campylobacters remains dependent on the selective media and techniques used, and in their letter to the editor, Bolton et al. raised the question: “what are we missing”? A large number of comparative studies and evaluations of conventional methods have preceded and followed that question, with McClurg and colleagues repeating the question 15 years later; fundamentally, studies have described the temperature of 43°C as prohibitive for the growth of some C. lari species, and the selective pressure of the antibiotics cefalothin, colistin, and polymyxin B, normally incorporated into most conventional media, as a reason for the low recovery of some strains of C. jejuni, C. coli, C. hyointestinalis, and non-thermophiles. More recent studies have found that filtration techniques are effective but time consuming, and that molecular methods of detecting campylobacters using DNA probes are not ideal for routine clinical use.

“Studies have described the temperature of 43°C as prohibitive for the growth of some Campylobacter lari subspecies”

Abbreviations: AAV, aztreonam amphotericin vancomycin; MIC, minimum inhibitory concentration.
tested: *H. fennellae* NCTC 11612 and *H. cinaedi* NCTC 11611. A reservoir of campylobacter strains and routine isolates from a preliminary study was preserved for suitability studies. Microaerobic incubation, identification, and biotyping procedures were adapted from Bolton et al., and efficacy, minimum inhibitory concentration (MIC), and challenge procedures by multipoint inoculation were adapted from Karmali et al.  

**Suitability studies: untried antibiotics and antagonism**

The suitability of the untried antibiotics was assessed by a disc diffusion method, in which six commercially prepared discs (Mast, Bootle, UK) chosen for their inhibitory action against Gram negative organisms were placed on to each lawned control strain. The discs contained the following antibiotics: tobramycin (10 mg), azlocillin (75 mg), imipenem (10 mg), amikacin (10 mg), piperacillin (75 mg), and aztreonam (30 mg), and zones of inhibition were recorded. Any possible antagonism when in combination with vancomycin was established by placing the commercially prepared discs of aztreonam (30 mg) and vancomycin (30 mg) 15 mm apart on non-selective blood plates, lawned with Oxford staphylococcus NCTC 6571 and *Escherichia coli* NCTC 10418 as controls, and inhibition zones were noted for radial symmetry.

**Evaluation of prototype AAV medium**

The suitability of the selective prototype medium was assessed by comparing it with modified CDA: 454 routine isolates—of which 385 were coliforms and 69 Gram positives—were spot inoculated in 0.3 µl volumes by a multipoint inoculation technique (Mast) on to modified CDA and AAV medium, growth selected, and saved before identification and MIC determination of aztreonam and vancomycin.  

One hundred and fifty hospital faecal samples were routinely cultured and all plates incubated microaerobically for three days with AAV medium at 37˚C and modified CDA at 43˚C. Procedures were standardised with *C. jejuni* NCTC 1168 and plates read on successive days for three days. Suspect campylobacter growth was confirmed by oxidase, Gram film, motility, and characteristic morphology, with isolates on AAV medium saved for identification and MIC determination.

**Table 1** Suitability study showing susceptibility of *Campylobacter* spp to the six antibiotics tested

<table>
<thead>
<tr>
<th>Antibiotic disc</th>
<th>Campylobacter strains</th>
<th>C fetus</th>
<th>C jejuni</th>
<th>C hyointestinalis</th>
<th>C coli</th>
<th>C lari</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipenem (10 mg)</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>Amikacin (10 mg)</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>Tobramycin (10 mg)</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>Azlocillin (75 mg)</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>Piperacillin (75 mg)</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>Aztreonam (30 mg)</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>Aztreonam (30 mg)</td>
<td>C upsaliensis</td>
<td>H cinaedi</td>
<td>H fennellae</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

R, resistant; S, sensitive.

**Table 2** Challenge studies showing growth of routine isolates (using multipoint) tested against modified CDA (43˚C) and AAV (37˚C) medium

<table>
<thead>
<tr>
<th>Medium</th>
<th>Total no of organisms tested</th>
<th>Total no of coliforms</th>
<th>Total no of Gram positives</th>
<th>Coliforms resistant on multipoint set</th>
<th>Gram positives resistant on multipoint set</th>
<th>Total resistant organisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified CDA</td>
<td>454</td>
<td>385</td>
<td>69</td>
<td>16 (3%)</td>
<td>2 (0.5%)</td>
<td>18 (4%)</td>
</tr>
<tr>
<td>AAV</td>
<td>454</td>
<td>385</td>
<td>69</td>
<td>22 (5%)</td>
<td>0</td>
<td>22 (5%)</td>
</tr>
</tbody>
</table>

AAV, aztreonam amphotericin vancomycin.

**Evaluation of prototype: growth efficacy, cephalothin, and thermotolerance**

Methods used a comparison of AAV medium with modified CDA, with serial 10 fold dilutions of NCTC campylobacter strains to 10^{-10} (vol/vol) spot inoculated by the multipoint method on to modified CDA and AAV media. All plates were incubated microaerophilically at 37˚C for 24 hours, and results were recorded as the lowest dilution to show visible growth. Campylobacters not isolated by modified CDA, but which grew on AAV at 37˚C, were re-challenged for susceptibility (inoculum diluted to 10^{-10} by plate-out) by plating on to non-selective charcoal agar at 37˚C at 43˚C using a cefradine disc of 30 mg, and incubated under microaerobic conditions for 48 hours.

**MIC, biotyping, and identification**

Doubling dilutions of the antibiotics vancomycin and aztreonam were prepared in a charcoal agar base in the range 0.2–256 mg/litre, and preserved NCTC campylobacter strains, clinical strains, and routine contaminants that grew on AAV medium (37˚C) were recultured and spot inoculated on to each set of prepared plates. Growth was recorded by Mastascan and MIC values read as the lowest concentration giving visible growth. The coliforms were identified using the API E kit (bioMérieux, Marcy-L’Etoile, France), and a simplified biotyping scheme adapted from Penner" was used for the identification of campylobacters.

**Table 3** Numbers of campylobacter strains isolated over three days of incubation on modified CDA (43˚C) and AAV (37˚C) medium (150 stool samples)

<table>
<thead>
<tr>
<th>No of isolates</th>
<th>Medium</th>
<th>No of isolates</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified CDA</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td>10 (7%)</td>
</tr>
<tr>
<td>AAV</td>
<td>9</td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td>14 (9%)</td>
</tr>
</tbody>
</table>

AAV, aztreonam amphotericin vancomycin.
faecal samples, 14 (9%) campylobacters were isolated on AAV inhibited by AAV medium (table 2). From 150 routine patient samples, however, the growth of all Gram positive bacteria tested was observed to grow on AAV medium compared with 16 on modified CDA; this exception being provided by a “wild-type” clinical strain of C. upsaliensis NCTC 11612, and H. fennelliae. C. upsaliensis NCTC strains with the exception of C. jejuni subsp. doylei grew on AAV medium giving a MIC value of >256 mg/mlitre to aztreonam and vancomycin, with the exception of C. upsaliensis NCTC 11926, H. fennelliae NCTC 11612, and H. cinaedi NCTC 11611, each with a MIC of 4 mg/mlitre to aztreonam and vancomycin (table 5). The MIC values for campylobacter strains from earlier work and the pilot study were within the range of 128–256 mg/mlitre, with one exception being provided by a C. jejuni isolate from a child, which had a MIC value of 128 mg/mlitre. The eight coliforms that failed to grow when re-challenged on AAV medium gave MIC values of 2–128 mg/mlitre for aztreonam and a MIC value > 256 mg/mlitre for vancomycin; in addition, the four Lactobacilli spp, with MIC values of 32–64 mg/litre for vancomycin and MIC values of 128–256 mg/mlitre for aztreonam, were sensitive when re-challenged. An Enterococcus spp re-grew on AAV medium giving a MIC value of >256 mg/mlitre for both aztreonam and vancomycin.

**RESULTS**

**Suitability studies**

The aztreonam disc (30 mg) showed no inhibitory action against C. jejuni NCTC 11168, C. coli NCTC 11366, C. lari NCTC 11352, C. jejuni subsp. doylei, C. hyointestinalis, C. fetus subsp. fetus (table 1), although it did not inhibit C. upsaliensis NCTC 11926, H. fennelliae NCTC 11612, and H. cinaedi NCTC 11611. A combination of aztreonam and vancomycin showed no antagonism and supported the growth of all campylobacter NCTC strains with the exception of C. upsaliensis NCTC 11926, H. fennelliae NCTC 11612, and H. cinaedi NCTC 11611; however, a “wild-type” clinical strain of C. upsaliensis grew on AAV medium after 48 hours of incubation (table 1).

**Challenge studies: isolation and contamination**

No significant difference was shown between the selectivity of both media against Gram negative bacteria: 22 coliforms grew on AAV medium compared with 16 on modified CDA; however, the growth of all Gram positive bacteria tested was inhibited by AAV medium (table 2). From 150 routine patient faecal samples, 14 (9%) campylobacters were isolated on AAV medium at 37°C, nine of which grew after 24 hours of incubation, compared with 10 (7%) campylobacters on modified CDA (43°C), five of which grew after 24 hours of incubation (table 3). After one day of incubation, contamination on AAV medium (37°C) remained minimal, with 5% of plates demonstrating mainly coliform contaminants—for example, E. coli, Enterobacter cloacae, Citrobacter freundii, and a rare colony of Acinetobacter spp, compared with 14% contamination on modified CDA (43°C). If contamination was assessed separately for each day, a reverse trend was seen on the second and third days when 19% and 14% of AAV plates (37°C), respectively, showed contamination by facultative aerobic organisms (such as Lactobacilli spp, Enterococcus spp, and yeasts) compared with 7% of modified CDA plates (43°C) on both days (table 4).

**Growth efficacy, biotyping, and MIC values**

AAV medium proved slightly more successful in supporting the growth of campylobacter NCTC strains, but C. upsaliensis NCTC 11926, H. fennelliae NCTC 11612, and H. cinaedi NCTC 11611 did not grow on this medium. Of the 14 campylobacters isolated, 10 were identified as C. jejuni; two as C. coli, one of which was isolated on both AAV (37°C) and modified CDA (43°C) on the third day of incubation (table 3), and the second of which was isolated only on AAV (37°C); the two remaining campylobacters that grew were identified as C. jejuni subsp. doylei. All campylobacter NCTC strains showed a MIC of 256 mg/mlitre to aztreonam and vancomycin, with the exception of C. upsaliensis NCTC 11926, H. fennelliae NCTC 11612, and H. cinaedi NCTC 11611, each with a MIC of 4 mg/mlitre to aztreonam and vancomycin (table 5). The MIC values for campylobacter strains from earlier work and the pilot study were within the range of 128–256 mg/mlitre, with one exception being provided by a C. jejuni isolate from a child, which had a MIC value of 128 mg/mlitre. The eight coliforms that failed to grow when re-challenged on AAV medium gave MIC values of 2–128 mg/mlitre for aztreonam and a MIC value > 256 mg/mlitre for vancomycin; in addition, the four Lactobacilli spp, with MIC values of 32–64 mg/litre for vancomycin and MIC values of 128–256 mg/mlitre for aztreonam, were sensitive when re-challenged. An Enterococcus spp re-grew on AAV medium giving a MIC value of >256 mg/mlitre for both aztreonam and vancomycin.

**DISCUSSION**

No one medium fulfils all the criteria for the isolation of campylobacter; this phrase remains the topic for a discussion for campylobacter isolation. In this study, aztreonam proved to be non-inhibitory for six campylobacter NCTC reference strains and, importantly, vancomycin was found to be non-antagonistic to aztreonam. Therefore, it was initially thought that campylobacters might be inherently resistant to aztreonam, because antibiotic susceptibility studies by Rittenbury had shown that the beta lactam antibiotic aztreonam bound poorly to the penicillin binding protein sites of microaerophilic and aerobic bacteria. However, this theory was quickly disproved with the sensitivity of C. upsaliensis NCTC 11296 to aztreonam. AAV medium supported the growth of six NCTC campylobacter reference strains and grew a “wild-type” clinical strain of C. upsaliensis, and some complimentary antibiotic activity was exhibited between the antibiotics aztreonam and vancomycin. This last fact would enhance selective pressure and provide an explanation for the equal activity of AAV medium to modified CDA in inhibiting the growth of coliforms and Gram positive contaminants.

In a small comparative study (150 samples), AAV (37°C) was more successful in isolating campylobacters on the first day of incubation: nine campylobacters were isolated on AAV (37°C) medium compared with five on modified CDA (43°C). Medium efficacy provides one explanation in that AAV medium showed more ability to support the growth of...
Campylobacter spp, but temperature and cephalothin tolerance studies provided no clear indication of why four more campylobacters were isolated on AAV medium at 37°C. All four strains grew equally well at 37°C and 43°C on non-selective charcoal medium and all were resistant to cephalothin. Equally, each isolate gave MIC values ≥ 256 mg/litre for vancomycin and aztreonam, but one isolate was identified as C. coli, which is generally more fastidious than C. jejuni. It would have been useful to have estimated MIC values for cefoperazone, but time limits did not permit this. AAV would have been useful to have estimated MIC values for vancomycin and aztreonam, but one isolate was identified in the study (50 strains) all had MIC values > 256 mg/litre for aztreonam and vancomycin. Because these MIC values differed from the other Lactobacilli spp isolated in the study, these organisms may have derived from the reagents and not from the faeces. However, it was shown that blood protein probably bound to the deoxycholate component of the charcoal basal agar, reducing the inhibitory effect of deoxycholate over contaminants resistant to aztreonam and vancomycin. Once this procedure was discontinued, and 7% horse blood omitted from the preparation of the AAV plates, rates of contamination returned to the same proportions seen on the first day of incubation; however, the overall results were slightly distorted because of this additional procedure.

This early confirmation of culture and isolation could remove some of the delays seen at present and provide the clinician with an option for rapid treatment.

REFERENCES


Take home messages

- AAV (aztreonam amphotericin vancomycin) campylobacter selective medium supported the growth of six campylobacter strains, although it did not support the growth of the C. upsaliensis NCTC strain
- In the pilot study (150 samples), AAV medium improved rates of isolation, particularly on the first day, which could be clinically relevant
- Contamination rates were low
- Further studies are indicated